Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2023 09:14 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
March 02, 2023 16:14 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
March 01, 2023 07:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

A single dose of CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model when compared to placeboCD388 was generally...
February 28, 2023 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara to Present at ESMO Targeted Anticancer Therapies Congress

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
February 14, 2023 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
February 01, 2023 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program

SAN DIEGO and SHANGHAI, China, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the...
January 25, 2023 07:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive candidiasis in over a decade ...
January 04, 2023 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
December 01, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
November 29, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right